{"title":"Mesenchymal stem cells: A new strategy for the treatment of femoral head necrosis","authors":"Feng Tian , Jiakang Peng , Yongqing Xu , Chuan Li","doi":"10.1016/j.reth.2025.07.008","DOIUrl":"10.1016/j.reth.2025.07.008","url":null,"abstract":"<div><div>Avascular necrosis of the femoral head (AVFH) is an orthopaedic disease triggered by ischaemic injury that is characterized by structural destruction of the femoral head and loss of function and severely affects the quality of life of patients. Currently, core decompression, bone grafting with vascularized tips, and artificial hip replacement are the main surgical treatment options used in clinical practice; however, these methods generally have limitations, such as trauma, high cost, and long postoperative recovery periods, which impose significant physiological and economic burdens on patients. In recent years, mesenchymal stem cells (MSCs) have shown great potential in the field of bone tissue engineering because of their unique biological properties. MSCs can self-renew and undergo multidirectional differentiation into osteoblasts, chondrocytes, and endothelial cells, and can also regulate the local microenvironment and promote the vascularization of the hip through the secretion of biologically active substances. MSCs can regulate the local microenvironment and promote new blood vessel and bone tissue regeneration through the secretion of growth factors, cytokines, and exosomes. The advantages of MSCs, such as easy access to materials, strong proliferation ability in vitro and stable osteogenic differentiation potential, make them ideal seed cells for femoral head necrosis treatment. However, ANFH treatment with MSCs faces many challenges: (1) the number of MSCs homing to lesion areas after intravenous infusion is limited; (2) the survival time and biological behaviour of locally injected MSCs are still unclear; (3) the mechanism of the interaction between MSCs and host cells has yet to be elucidated; and (4) efficiently modulating the microenvironment of necrotic areas for tissue regeneration needs to be investigated in depth. There are various innovative strategies to address these issues: enhancing the homing ability and in vivo stability of MSCs through genetic engineering; combining MSCs with biomaterials, such as hydrogels, to achieve precise targeting and slow release; and developing drug delivery systems for MSCs to improve therapeutic efficacy. In this paper, we systematically reviewed the pathological microenvironmental characteristics of femoral head necrosis and discuss the potential application, mechanism, existing problems, and solutions of MSCs in ANFH treatment in detail, providing a new theoretical basis and research direction for advancing the clinical treatment of femoral head necrosis.</div></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"30 ","pages":"Pages 421-429"},"PeriodicalIF":3.4,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144687177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Evaluation of the usage of more than 50 sheets of autologous cultured epidermis (JACE®) sheets in treating patients with severe burns beyond insurance coverage limits","authors":"Yoshimi Yashiro , Masukazu Inoie","doi":"10.1016/j.reth.2025.07.005","DOIUrl":"10.1016/j.reth.2025.07.005","url":null,"abstract":"<div><h3>Background</h3><div>Autologous cultured epidermis, JACE®, Japan's first regenerative medical product, is used as the standard treatment for wound closure in patients with severe burns. Although this product is listed for national health insurance in Japan, medical institutions place orders for JACE® beyond the limit of 50 sheets calculated for insurance coverage (insurance coverage limit) for lifesaving purposes. Therefore, the manufacturer and distributor continue to provide an excess amount, free from humanitarian considerations.</div></div><div><h3>Methods</h3><div>As a project supported by the Ministry of Economy, Trade, and Industry, the authors planned and conducted a non-interventional survey on the usage of JACE® from June 21, 2023, to February 29, 2024. In cases where more than 50 sheets of JACE® were used for patients with severe burns, information obtainable at the manufacturing stage and post-treatment feedback from physicians in charge were collected, and the requirement for JACE® were reviewed.</div></div><div><h3>Results</h3><div>During the survey period, interviews were conducted with physicians in charge at 30 institutions that placed orders for JACE® for the treatment of patients with severe burns. Of 43 patients, 13 received51 or more JACE® sheets. All were used at the request of the physician in charge and were confirmed to contribute to epithelialization, which closes burn wounds and saves lives. The mean age of the 13 patients who received 51 or more JACE® sheets (group H) was 53.2 years, which was lower than the63.1 years in the 30 patients who received 50 or fewer sheets (group L). The mean injured area was 55.9 % in group H and was clearly larger than the 37.0 % in group L. All patients with an injured area of 70 % or more were in group H, and three patients who received 100 or more JACE® sheets, with the highest reaching 165 sheets. In group H, JACE® tended to be used in younger patients with a large injured area and in elderly patients with a small injured area. A total of 434 sheets were provided to medical institutions free of charge to the 13 patients in group H.</div></div><div><h3>Conclusions</h3><div>Among the number of JACE® orders placed for the treatment of patients with severe burns, 30 % received more sheets than the insurance coverage limit; of the total number of sheets, 20.7 % were provided free of charge to medical institutions. Given this situation, the 50-sheet limit for insurance reimbursements need to be revisited.</div></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"30 ","pages":"Pages 415-420"},"PeriodicalIF":3.4,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144655445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Culturing Potential: advances in ex vivo cell culture systems for haematopoietic cell-based regenerative therapies","authors":"Ayano Sugiyama-Finnis, Satoshi Yamazaki","doi":"10.1016/j.reth.2025.07.001","DOIUrl":"10.1016/j.reth.2025.07.001","url":null,"abstract":"<div><div>Stem-cell derived therapies are an essential pillar in the field of regenerative medicine, utilising stem cell self-renewal and multipotent or pluripotent differentiation capabilities to give rise to functional, specialised cells to repair and restore tissue function. Haematopoietic cell therapies have been pivotal to the development of the regenerative medicine field and continue to hold significant promise enabled by recent technical innovation in cell culture approaches that have expanded their therapeutic potential. The development of novel cell culture protocols that allow for the standardised ex vivo expansion of haematopoietic stem cells (HSCs) has facilitated the exploration of umbilical cord blood allogeneic HSC transplantation. Directed differentiation protocols of HSCs, embryonic stem cells and induced pluripotent stem cells, to selectively produce a desired haematopoietic cell type in a donor-independent manner, has broadened the scope for haematopoietic cell-based regenerative therapy. Furthermore, the integration of genome modification or gene editing with these protocols have allowed for corrective autologous HSC transplantation as well as the ability to confer haematopoietic cells with enhanced or novel therapeutic functions. Despite this, realising large-scale clinical translation remains challenging. Current efforts aim to move towards chemically defined culture systems, improving the efficiency and reproducibility of lineage-specific differentiation with an emphasis on compatibility with genome modification and gene-editing protocols for the scalable production of high-quality, efficacious and safe cellular therapies. In this review, we summarise the key milestones and technical advancements in the field in addition to the outstanding questions to be addressed.</div></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"30 ","pages":"Pages 403-414"},"PeriodicalIF":3.4,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144655444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shuaiwen Hu , Shaogeng Wang , Xiaomao Yang , Ping Li , Zhiguo Li , Bin Luo , Yujie Liang , Xiaohua Pan
{"title":"Exosomes promise better bone regeneration","authors":"Shuaiwen Hu , Shaogeng Wang , Xiaomao Yang , Ping Li , Zhiguo Li , Bin Luo , Yujie Liang , Xiaohua Pan","doi":"10.1016/j.reth.2025.06.020","DOIUrl":"10.1016/j.reth.2025.06.020","url":null,"abstract":"<div><div>Fractures primarily result from high-energy trauma, leading to structural discontinuity of bone tissue. Contemporary therapeutic approaches continue to face persistent challenges including nonunion, infection, and inflammatory complications that pose significant clinical management difficulties. Emerging evidence demonstrates that extracellular vesicles (EVs), particularly exosomes, serve as critical mediators in diverse pathophysiological processes. Accumulating studies reveal that exosomal cargos enhance osteogenesis and angiogenesis through dynamic regulation of cellular components and molecular networks within the bone remodeling microenvironment, thereby potentiating fracture healing cascades. This comprehensive review systematically examines the mechanistic contributions of exosomes in coordinating osteoblastic differentiation, osteoclastic activity modulation, and neovascularization processes. In addition, we describe the role of exosomes from different cellular sources (e.g., mesenchymal stem cells, endothelial progenitor cells, and osteoblasts) in fracture repair. Finally, this paper elaborates on the potential challenges and future directions for the development of novel exosome-based therapeutic strategies for clinical fracture repair.</div></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"30 ","pages":"Pages 389-402"},"PeriodicalIF":3.4,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144634298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Assessment of the official national insurance coverage of regenerative medical products for ophthalmic diseases in Japan following regulatory approval","authors":"Kenichi Kimura , Kojiro Imai , Morio Ueno , Chie Sotozono","doi":"10.1016/j.reth.2025.07.003","DOIUrl":"10.1016/j.reth.2025.07.003","url":null,"abstract":"<div><h3>Introduction</h3><div>Recently, significant progress has been made in the field of regenerative medicine in Japan for the treatment of ophthalmic diseases, with a notable emphasis placed on clinical research and practical applications, and in 2014, one significant development was the initiation of the world's first clinical research using iPS cells for age-related macular degeneration. In addition, three regenerative medical products for the treatment of limbal stem cell deficiency, a rare and intractable ocular surface disease, have recently been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) under the Pharmaceuticals, Medical Devices, and Other Therapeutic Products Act (PMD Act). In order to expedite the practical implementation of regenerative medicine, the PMD Act presented a new category for regenerative medical products alongside the two categories that currently exist (i.e., 'pharmaceutical products' and 'medical devices'). However, within the current official Japanese national insurance coverage plan, there is no category designated for 'regenerative medical products'. Although the approval system for regenerative medical products differs from country to country (i.e., the United States Food and Drug Administration (U.S. FDA), the European Medicines Agency (EMA), etc.), in Japan, they are approved by the Japanese MHLW and PMDA. When manufacturers seek newly approved regenerative medical products in Japan to be incorporated within those listed in the Japanese national insurance coverage plan, the products are classified as either 'pharmaceutical products' or 'medical devices' and are reviewed by the Central Social Insurance Medical Council (\"Chuikyo\", in Japanese) of the Japanese MHLW. Although the responsibility for applying for regulatory approval and insurance coverage lies with the manufacturer, as the developer who conducted the clinical study and the investigator-initiated clinical trial for two ophthalmic regenerative medical products (i.e., Sakracy® and Vyznova®), we perceived that the period from regulatory approval to insurance coverage listing for these two products was longer than for other ophthalmic regenerative medical products. These experiences became the research question and the focus was on ophthalmic regenerative medical products, with the rationale behind this submission being that the dissemination of our experience will be of benefit to all clinical researchers and manufacturers. Hence, the purpose of this present study was to investigate the insurance coverage of regenerative medical products for ophthalmic diseases in Japan from the aspect of specific coverage-related categories.</div></div><div><h3>Methods</h3><div>In this study, we investigated newly approved regenerative medical products for ophthalmic diseases in Japan after the Revised Pharmaceutical Affairs Act came into effect in 2014. The insurance coverage ","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"30 ","pages":"Pages 384-388"},"PeriodicalIF":3.4,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144604785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Fabrication of Piezo1 protein encapsulated pressure-sensitive multifunctional hydrogel in modulating cellular response and wound healing in pressure ulcer conditions","authors":"Jing Ning, Feng Li, Zhi Xin Pei, Zhi Li","doi":"10.1016/j.reth.2025.06.014","DOIUrl":"10.1016/j.reth.2025.06.014","url":null,"abstract":"<div><div>Pressure ulcers (PUs) are prevalent skin lesions characterized by significant morbidity, susceptibility to infection, and a complex healing process. This study aims at the synthesis of piezo1 protein-encapsulated, pressure-sensitive multifunctional hydrogel to modulate cellular response and promote wound healing in PUW conditions. The hydrogel synthesized from carboxyl methyl cellulose hydrogel exhibits the optimal swelling ratio and is found to have a high storage modulus (G′). This shows the mechanical strength and viscoelastic nature of the synthesized hydrogel. The PP encapsulation and releasing efficiency has been analyzed, and this proves the prolonged activation of mechanotransduction properties. <em>In vitro</em> analysis on 3T3 and HUVEC proves a high proliferation rate and proves to have an enhanced cell migration rate in hypoxia-induced cell lines. The angiogenesis was also found to be increased, which is indicated by tube formation that enhances the wound healing rate. The pressure ulcer animal model was analyzed for 3, 7, 10, and 14 days, and the wound healing rate. The reduction in inflammatory cytokine expression and the collagen deposition rate has been analyzed. By day 14, the wound closure reached above 91%, significantly higher than the untreated group. These findings demonstrate that PP-MH enhances cell proliferation and angiogenesis, thereby acts as a promising strategy for advanced pressure ulcer management.</div></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"30 ","pages":"Pages 371-383"},"PeriodicalIF":3.4,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144596716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Current challenges and future directions of ATMPs in regenerative medicine","authors":"Fatemeh Abbasi Kakroodi , Elaheh Khodadoust , Marzieh Alizadeh , Reyhaneh Sadat Hayaei Tehrani , Pedram Asadi Sarabi , Mohammad Rahmanian , Massoud Vosough","doi":"10.1016/j.reth.2025.06.017","DOIUrl":"10.1016/j.reth.2025.06.017","url":null,"abstract":"<div><div>Advanced therapy medicinal products (ATMPs) represent a groundbreaking category of medications that utilize biological-based products to treat or replace damaged organs. It offers potential solutions for complex diseases through gene therapy, somatic cell therapy, tissue engineering, and combined therapies. Although ATMPs have offered significant improvement for a variety of severe illnesses, their progressive development is faced with numerous challenges. Some of these challenges are current complexities in their manufacturing, such as scaling up, scaling out, product efficacy, packaging, storage, stability, and logistic concerns. Other challenges include manufacturing, efficacy, and scaling up of ATMPs, as well as establishing Good Manufacturing Practice (GMP)-compliant processes that align with product specifications derived from non-clinical studies conducted under Good Laboratory Practice (GLP). Additionally, safety concerns such as tumorigenesis are potential. Regulatory and ethical concerns, along with the need for standardization and clear clinical guidelines, are also critical obstacles. To address these challenges, novel technologies such as organoids, artificial intelligence, dynamic culture systems, and biobanking are being explored, providing new opportunities to enhance the consistency, scalability, and precision of ATMP production. Development in artificial intelligence (AI) technology helped scientists to address monitoring concerns, automation, and data management. Introducing advanced guidelines in biobanking helps researchers to overcome the storage and stability concerns. Organoid technology holds a significant promise in overcoming the challenges associated with preclinical and modeling of ATMPs by providing more accurate models for diseases, drug screening, and personalized medicine. This article reviews the current challenges in ATMP manufacturing and application, highlights the advancements in technology that are paving the way for improved therapeutic strategies, and offers future perspectives on overcoming these barriers.</div></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"30 ","pages":"Pages 358-370"},"PeriodicalIF":3.4,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144580666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The role of telomeres in leukemic stem cells function","authors":"Raheleh Farahzadi , Behnaz Valipour , Ezzatollah Fathi , Sakhavat Abolhasani","doi":"10.1016/j.reth.2025.06.019","DOIUrl":"10.1016/j.reth.2025.06.019","url":null,"abstract":"<div><div>The length of a telomere provides insight into the replication history of a cell. Notwithstanding the fact that the telomerase enzyme is produced by stem and progenitor cells, a considerable proportion of the documented telomere degradation takes place at these levels. Sequential transplantation remains a challenge for hematopoietic stem cells (HSCs) transfected with telomerase, despite their ability to maintain telomere length. To optimize stem cell proliferation, additional parameters must be considered [1]. In contrast, unregulated telomere depletion induced by HSCs appears to play a significant role in the pathogenesis of bone marrow failure, as demonstrated by dyskeratosis congenita. It implies that telomerase dysfunction serves as a prevalent ultimate pathogenic mechanism in this heterogeneous hereditary disorder. Although this condition is not well defined, acquired marrow failure syndromes have been linked to mutations in critical telomerase components. In light of the discovery of leukemic stem cells (LSCs) and the desire to develop anti-leukemia treatments for this population, a comprehensive understanding of the telomerase biology within this cell compartment is required. Further research must employ LSC-rich primary samples that have been selected. A more thorough understanding of the correlation between telomere length and telomerase regulation in this specific population may facilitate the creation of innovative approaches or small molecule inhibitors that specifically target the telomerase enzyme complex.</div></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"30 ","pages":"Pages 351-357"},"PeriodicalIF":3.4,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144580664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Corrigendum to “Salvianolic acid A facilitates cartilage repair in knee osteoarthritis model rats by promoting WDR5 expression” [Regen Therapy 29C (2025) 77–90/880]","authors":"Hua He , Dali Dong","doi":"10.1016/j.reth.2025.05.017","DOIUrl":"10.1016/j.reth.2025.05.017","url":null,"abstract":"","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"30 ","pages":"Pages 339-340"},"PeriodicalIF":3.4,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144571162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Robert M. Rusch , Emi Inagaki , Kentaro Ago , Tetsu Yoshida , Yui Ueno , Hidenori Nonaka , Hideyuki Okano , Masaya Nakamura , Shigeto Shimmura
{"title":"Tracking adipose-derived mesenchymal stromal cells in the eye: Integrating IVIS imaging and Alu PCR for enhanced detection of human cells","authors":"Robert M. Rusch , Emi Inagaki , Kentaro Ago , Tetsu Yoshida , Yui Ueno , Hidenori Nonaka , Hideyuki Okano , Masaya Nakamura , Shigeto Shimmura","doi":"10.1016/j.reth.2025.06.018","DOIUrl":"10.1016/j.reth.2025.06.018","url":null,"abstract":"<div><h3>Introduction</h3><div>Cell transplantation finds broad applications in medical science, with applications ranging from stem cell therapies to cancer research. Despite its widespread use, inherent risks such as tumor formation and immune rejection necessitate a comprehensive understanding of transplanted cell dynamics. Thus, tracing cellular behavior is a critical aspect of medical research, particularly in the context of cell transplantation. The capacity to precisely monitor and evaluate the behavior of transplanted cells over time is essential for evaluating therapeutic effectiveness, safety profiles, and long-term consequences.</div><div>Traditional imaging approaches, like Z-stack and overlay images, present challenges due to limitations in sample size, determining cell location and migration, and only observing the one moment of the therapeutical application. However, recent advancements in imaging technologies have significantly improved our ability to trace cellular behavior in vivo. Bioluminescence imaging (BLI) has emerged as a powerful tool for non-invasive, real-time monitoring of cell survival, proliferation, and distribution in animal models. The in vivo imaging system (IVIS) for instance, focuses on its non-invasive nature and versatile applications in real-time investigations. Genetically modified cells express luciferase, allowing for the detection of light emission when luciferin is administered. BLI offers high sensitivity and the ability to track cells over extended periods, providing crucial information about cell engraftment and persistence.</div></div><div><h3>Method</h3><div>Transfecting human adipose mesenchymal stem cells (adMSCs) with a lentiviral vector encoding firefly luciferase under the CAG promoter (CAG-ffLuc-cp156), which allows to establish a comprehensive understanding of adMSC behavior, distribution, and therapeutic safety, addressing a critical obstacle in the clinical evaluation of stem cell applications. The study tracked transfected adMSCs over seven days, with subsequent analysis of human DNA distribution by Alu-PCR.</div></div><div><h3>Result</h3><div>Data indicates adMSCs disappear from the recipient by day 7, corroborated by the absence of human DNA in tested organs. The primary objective is to present a methodology for subconjunctival delivery, investigating the biodistribution and migration of adMSCs post-injection, with potential implications for various cell therapies.</div></div><div><h3>Conclusion</h3><div>This study provides a valuable methodology for investigating cell behavior post-injection, contributing to the optimization of cell therapies for clinical applications. Furthermore, it highlights the safety of applying adMSCs with relatively low potential of tumorgenicity.</div></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"30 ","pages":"Pages 333-338"},"PeriodicalIF":3.4,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144564090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}